T-Cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4800-4808

  Boorjian, Stephen A ^a   Sheinin, Yuri ^a,b   Crispen, Paul L ^a   Farmer, Sara A ^a   Lohse, Christine M ^a   Kuntz, Susan M ^b   Leibovich, Bradley C ^a   Kwon, Eugene D ^a,b   Frank, Igor ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; PARAFFIN; PROGRAMMED DEATH LIGAND 1; PROTEIN B7 H3; PROTEIN PD 1; REGULATOR PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CD274 PROTEIN, HUMAN; CD276 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UROGENITAL TRACT CANCER; UROTHELIUM; BIOSYNTHESIS; CARCINOMA; COHORT ANALYSIS; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CARCINOMA; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 51049096135     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0731     Document Type: Article

References (50)

1. Jemal A, Siegel R. Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57: 43-66.
2. Herr HW, Bean MA, Whitmore WF, Jr. Decreased ability of blood leukocytes from patients with tumors of the urinary bladder to act as stimulator cells in mixed leukocyte culture. Cancer Res 1976:36: 2754-60.
3. Mukamel E, Shohat B, Servadio C. Immunological profile of patients with transitional cell carcinoma of the bladder. Br J Ural 1982:54:11-5.
4. Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmstrom PU, Totterman TH. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 2007:177:353-8.
5. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007:13:1757-61.
6. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007;56:1173-82.
7. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007;109: 1499-505.
8. Krambeck AE, Thompson RH, Dong H, et al. B7-4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006:103:10391-6.
9. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005:65: 1089-96.
10. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006:66:3381-5.
11. Thompson RH, Webster WS, Cheville JC, et al. B7-1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology 2005;66:10-4.
12. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004:101: 17174-9.
13. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094-100.
14. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits Tcell activation. Proc Natl Acad Sci U S A 2003;100: 10388-92.
15. Dong H, Strome SE, Salomao DR, et al. Tumorassociated B7-1 promotesT-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8: 793-800.
16. Dong H, Zhu G, Tamada K, Chen L. B7-1, a third member of the B7 family, co-stimulatesT-cell proliferation and interleukin-10 secretion. Nat Med 1999;5: 1365-9.
17. Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003;4:899-906.
18. Ling V, Wu PW, Spaulding V, et al. Duplication of primate and rodent B7-3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 2003;82:365-77.
19. Roth TJ, Sheinin Y, Lohse CM, et al. B7-3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007;67:7893-900.
20. Chen L. Co-inhibitory molecules of the B7-28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-47.
21. Carreno BM, Collins M. BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol 2003; 24:524-7.
22. Zha Y, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1. Crit Rev Immunol 2004;24: 229-37.
23. Chapoval Al, Ni J, Lau JS, et al. B7-3: a costimulatory molecule forTcell activation and IFN-γ production. Nat Immunol 2001;2:269-74.
24. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007;13:5271-9.
25. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection byTcell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64:1140-5.
26. Iwai Y, Ishida M, Tanakac Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7.
27. Stavropoulos NE, loachim E, Hastazeris K, Goussia A, Agnantis NJ. Lymphocyte subsets in superficial bladder cancer: correlation with biological activity of the tumours. Anticancer Res 1998;18:2037-40.
28. Hilmy M, Campbell R, Bartlett JM, McNicol AM, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2006;95:1234-8.
29. Bevers RF, Kurth KH, Schamhart DH. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 2004;91:607-12.
30. Sharma P, Shen Y, Wen S, et al. CD8 tumorinfiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007;104:3967-72.
31. Kastelan Z, Lukac J, Derezic D, et al. Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res 2003;23:5185-9.
32. Lukens JR, Cruise MW, Lassen MG, Hahn YS. Blockade of PD-1/B7-1 interaction restores effector CD8+ Tcell responses in a hepatitis C virus core murine model. J Immunol 2008;180:4875-84.
33. Fleshner N, Kapusta L, Ezer D, Herschorn S, Klotz L. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 2000;164:1177-82.
34. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155: 495-9; discussion 9-500.
35. Skinner DG, Daniels JR. Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-64; discussion 64-7.
36. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007;177:437-43.
37. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
38. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006: 176:2414-22; discussion 22.
39. Madersbacher S, Hochreiter W, Burkhard F, et al Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690-6.
40. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy Cancer 2008;112:315-25.
41. Silva Neto B, Smith GL, Mandeville JA, et al. Prognostic significance of altered p120 ctn expression in bladder cancer. BJU Int 2008;101:746-52
42. Baumgart E, Cohen MS, Silva Neto B, et al. Identification and prognostic significance of an epithehalmesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007;13:1685-94.
43. Hoel DG, Ron E, Carter R, Mabuchi K. Influence of death certificate errors on cancer mortality trends J Natl Cancer Inst 1993;85:1063-8.
44. Grossman HB, Natale RB. Tangen CM, et al Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 2003:349:859-66.
45. Hollenbeck BK, Ye Z. Wong SL, Montie JE. Birkmeyer JD. Hospital lymph node counts and survival after radical cystectomy. Cancer 2008;112:806 12
46. Chapman PB, Houghton AN. Non-antibody immunotherapy of cancer. Curr Opin Immunol 1993;5:726-31.
47. Soloway MS. Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002:167:1573-83.
48. Yutkin V, Pode D, Pikarsky E, Mandelboim O. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guenn thera py: a pilot study. J Urol 2007;178:2660-4.
49. Phan GQ. Yang JC, Sherry RM, et al Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci U S A 2003;100:8372-7.
50. Egen JG, Kuhns MS. Allison JP CTLA-4 new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-8.